Coppell Advisory Solutions’s Recursion Pharmaceuticals RXRX Stock Holding History

Coppell Advisory Solutions’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$927	Buy	+94	New	+$670	﹤0.01%	1428

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Coppell Advisory Solutions's RXRX Position: Q4 2023 in Review

Coppell Advisory Solutions opened a new position in Recursion Pharmaceuticals (RXRX) in Q4 2023: 94 shares worth $927. The stake represents ﹤0.01% of the portfolio and ranks #1428 among its holdings.

199 funds tracked by Wall St. Rank hold RXRX as of Q4 2023.

Coppell Advisory Solutions held 94 shares of Recursion Pharmaceuticals worth $927 as of Q4 2023.
Recursion Pharmaceuticals was a new Coppell Advisory Solutions position in Q4 2023.
Recursion Pharmaceuticals made up ﹤0.01% of Coppell Advisory Solutions's portfolio in Q4 2023, its #1428 holding.
199 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2023.

Based on Coppell Advisory Solutions's 13F filing for Q4 2023, filed 14 Feb 2024.